IndustryCompany release

Sarepta raises 2026 revenue floor after $323.8m third-quarter sales; DM1 and FSHD data due

🇺🇸 Sarepta Therapeutics, Inc. (SRPT) · Thu 05 Nov 2026

The gene therapy and exon-skipping company lifted the low end of its net product revenue guidance by $50m and trimmed expense guidance, with two muscle-disease datasets expected this quarter.

Sarepta Therapeutics reported third-quarter 2026 results on 5 November, posting net product revenue of about $323.8m. Elevidys contributed $83.5m, while the company's PMO products, its exon-skipping portfolio, brought in $240.3m.

The company raised the lower end of its 2026 net product revenue guidance by $50m, narrowing the range to $1.25bn-$1.3bn. It also lowered the top of its expense guidance by $25m.

On the pipeline, Sarepta expects multiple ascending dose data in the fourth quarter of 2026 for two programmes: SRP-1003 in myotonic dystrophy type 1 (DM1) and SRP-1001 in facioscapulohumeral muscular dystrophy (FSHD).

The company said it is preparing Phase 3 programmes and discussing both accelerated and traditional approval routes with the US Food and Drug Administration. The summary available does not give details of the trial designs, timelines or the agency's position.

What it means for your team

  • Regulatory teams should watch the Q4 DM1 and FSHD multiple ascending dose readouts, which are likely to shape the Phase 3 design and the choice of approval pathway discussed with FDA.
  • Market-access teams can note that the higher revenue floor rests on a PMO base of $240.3m for the quarter, set against $83.5m from Elevidys.
  • Accelerated approval, as a general matter, relies on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit and usually brings confirmatory-trial obligations. Any Sarepta filing along that route would need a plan for them.

Company's press release (SEC filing): Sarepta Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Sarepta Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →